Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane

Outlines Impact Of China Zero-COVID Policy

 
• By Anju Ghangurde

Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.

New Revenue Base For Cipla's US business • Source: Shutterstock

Cipla signaled a new revenue base for its US business in the fiscal second quarter, buoyed by the ongoing market share expansion of its partnered peptide asset lanreotide and the launch of generic Revlimid (lenalidomide).

Cipla’s 505(b)(2) hybrid lanreotide injection product has seen market share move up to 9.6% in the second quarter, from 4

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business